Sellas Life Sciences (SLS) director awarded 50,000 RSUs grant in 2026

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. director equity grant: Director John Varian received an award of 50,000 restricted stock units on January 7, 2026. These units will vest in full on December 1, 2026, as long as he continues to serve on the company’s Board of Directors through that date. Following this award, he beneficially owns 72,900 shares of SELLAS common stock in direct ownership. The RSUs were granted at a price of $0.00 per unit, reflecting a typical non-cash equity compensation grant to a board member.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Varian John

(Last) (First) (Middle)

C/O SELLAS LIFE SCIENCES GROUP, INC.,

7 TIMES SQUARE, SUITE 2503

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		50,000(1)	A	$0.00	72,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

	/s/ Daniel Bagliebter, Power of Attorney for: John Varian	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SELLAS (SLS) report for John Varian?

SELLAS Life Sciences Group, Inc. reported that director John Varian received an award of 50,000 restricted stock units on January 7, 2026, at a grant price of $0.00 per unit.

When do John Varian’s 50,000 RSUs at SELLAS (SLS) vest?

The 50,000 restricted stock units granted to director John Varian will vest in full on December 1, 2026, provided he continues to serve on SELLAS’s Board of Directors through that date.

How many SELLAS (SLS) shares does John Varian own after this Form 4 transaction?

After the reported award, director John Varian beneficially owns 72,900 shares of SELLAS Life Sciences Group, Inc. common stock in direct ownership.

Is the SELLAS (SLS) Form 4 transaction a purchase or a grant?

The Form 4 reflects an equity grant, not an open-market purchase. John Varian was awarded 50,000 restricted stock units at a grant price of $0.00 per unit as director compensation.

What condition applies to the vesting of John Varian’s RSUs at SELLAS (SLS)?

The 50,000 restricted stock units will vest only if John Varian continues to serve on SELLAS’s Board of Directors through December 1, 2026.

Does the SELLAS (SLS) Form 4 indicate indirect ownership for this award?

No. The filing shows that after the award, the 72,900 shares of SELLAS common stock are held with direct ownership by John Varian, with no nature of indirect ownership listed.